A panel of clinical specialists in Spain has established a structured framework of clinical indicators to help physicians identify disease progression and re-evaluate therapy in patients receiving treatment for Fabry disease. Developing dependable methods for tracking disease progression remains critical for optimizing ongoing therapies and supporting long-term health outcomes in individuals diagnosed with this condition.
To formulate the monitoring criteria, eight Spanish clinicians specializing in Fabry disease participated in a structured nominal group technique. The expert consensus targeted practical clinical markers, described as alerts of progression, designed to signal when a therapeutic reassessment is warranted for patients already on therapy.
The consensus process evaluated candidate monitoring parameters distributed across four designated clinical domains. These domains encompassed cardiac measures, renal parameters, neurological signs, and a category combining disease-specific and treatment-related biomarkers across different patient presentations.
The candidate parameters evaluated by the clinicians were initially compiled through a preparatory evidence review followed by detailed expert discussion. To objectively establish priorities among the candidate measures, each panelist was allocated up to five scoring points to distribute within each of the four clinical categories.
Parameters qualified as prioritized indicators if they secured fifteen percent or more of the maximum available points within their respective domain. Those indicators meeting this scoring threshold advanced to subsequent structured deliberations by the expert panel.
In the renal domain, prioritized parameters included a measurable decline in estimated glomerular filtration rate alongside increases in albuminuria. Cardiac surveillance criteria prioritized the progression of ventricular hypertrophy or the documented advance of myocardial fibrosis.
Within the neurological domain, the panel prioritized the occurrence of cerebrovascular events and the worsening of neuropathic pain. In the biomarker category, prioritized criteria centered on the elevation of globotriaosylsphingosine, or lyso-GB3, specifically when observed in combination with neutralizing antibodies and clinical deterioration.
The expert group selected these specific clinical indicators based on their clinical relevance, objective measurability, and consistency across patient sexes and distinct disease phenotypes. The resulting monitoring framework provides clinicians with a systematic foundation for tracking treated Fabry disease, offering potential to harmonize clinical monitoring routines and support patient care decisions.
Published as an open access position statement in the Orphanet Journal of Rare Diseases, the consensus report outlines guidance prepared by eight clinical specialists from Spain. The journal distributed this peer reviewed accepted manuscript early to accelerate access to the research, confirming that the citable document carries a permanent digital object identifier while awaiting publication of the final version of record.
From a methodological perspective, the framework reflects structured consensus derived from a nominal group technique rather than empirical findings from a prospective clinical trial. The expert panel designed these practical alerts of progression specifically for patients actively receiving treatment, establishing clear indicators to help clinicians determine when therapeutic reassessment is warranted. Because the evaluated parameters were selected for clinical relevance, objective measurability, and consistency across both sexes and different disease phenotypes, the recommendations offer a standardized baseline to coordinate clinical practices across diverse hospital centers. However, the position statement establishes expert consensus rather than direct proof of improved patient health outcomes, providing structured clinical guidance across cardiac, renal, neurological, and disease specific biomarker monitoring domains.
Subject of Research: Clinical consensus indicators for monitoring disease progression in Fabry disease
Article Title: Monitoring disease progression in fabry disease: insights from a structured nominal expert consensus
Article References: Barriales-Villa, R., Cristóbal-Bilbao, R., Goicoechea, M., Gutiérrez-Gutiérrez, G., Hermida, Á., Limeres-Freire, J., López-Mendoza, M., & Ortiz, A. (2026). Monitoring disease progression in fabry disease: insights from a structured nominal expert consensus. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-026-04650-6
Image Credits: AI Generated
DOI: 10.1186/s13023-026-04650-6
Keywords: Fabry disease, nominal group technique, disease progression, expert consensus, estimated glomerular filtration rate, albuminuria, ventricular hypertrophy, myocardial fibrosis, cerebrovascular events, neuropathic pain, lyso-GB3, neutralizing antibodies, cardiac monitoring, renal monitoring, rare diseases, clinical indicators
News Source: Ophelia Keating. (November 19, 2026). Expert Panel Establishes Consensus Indicators for Tracking Progression in Treated Fabry Disease. Scienmag.



